Ventyx Biosciences Inc. (NASDAQ: VTYX)
$2.95
+0.1100 ( +3.87% ) 211.4K
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Market Data
Open
$2.95
Previous close
$2.84
Volume
211.4K
Market cap
$206.56M
Day range
$2.79 - $3.03
52 week range
$1.87 - $38.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Dec 21, 2023 |
4 | Insider transactions | 1 | Dec 21, 2023 |
4 | Insider transactions | 1 | Dec 21, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
8-k | 8K-related | 12 | Dec 07, 2023 |
8-k | 8K-related | 12 | Nov 22, 2023 |